What does it look like to really live a full life – one that enriches and satisfies, that provides happiness and enables achievement? Abbott is talking to one million people worldwide to find out. And the answers aren’t as simple as you would think.
Does living fully look the same to an accountant in Shanghai as it does to an architect in New Delhi or a street artist in São Paulo? What about a factory worker in Detroit or a new mother in Berlin? In today’s hyperconnected world that is pulling us together in so many ways, how do our cultural differences, life experiences and personalities influence what it means to live a full life?
Early in this quest we’re seeing preliminary trends, like the role health plays in a full life in Shanghai and the importance of family in New York. We’ll have to see if this is confirmed as we go global with our research. The one thing that is becoming apparent is just how personal it gets when we talk to people about life.
This global quest is at the heart of what our company does—finding answers that have helped people live healthier, better lives for more than 125 years.
To view the multimedia release go to:
http://www.multivu.com/players/English/7611051-abbott-live-fully/
Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) released a new report, “A Decade of Innovation in Rare Diseases,” to document the significant progress made in the last 10 years in understanding a broad range of rare diseases and translating this knowledge into groundbreaking therapies for a variety of patient populations.
The report illustrates that more than 230 new medicines to treat rare or “orphan” diseases were approved by the U.S. Food and Drug Administration (FDA) in the last decade, and there are currently more than 450 orphan drugs in development.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7350554-phrma-report-innovation-rare-diseases/
SunPower (NASDAQ:SPWR) has once again raised the bar by introducing the highest-power solar panels available today for the residential market. In the United States, the company has launched its Next Generation Technology home solar panel called A-Series, delivering 400 and 415 watts of power. In Europe and Australia, homeowners can also now order a 400-watt solar panel from SunPower called Maxeon® 3. Each is the first home solar panel to deliver more than 400 watts in its region and is designed to deliver 60 percent more energy in the same amount of roof space over the first 25 years compared to conventional solar.
“SunPower is introducing the world’s first 400-watt residential solar panels as most in the industry are just crossing the 300-watt threshold for home solar,” said Jeff Waters, CEO of the SunPower Technologies business unit. “Our record-breaking cell technology and innovative research and development efforts have enabled us to fit more power capacity on rooftops than we ever have before. Our growing panel portfolio is delivering unprecedented value across global markets that goes unmatched by any other residential solar technology currently available.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8252054-sunpower-a-series-next-gen-solar-panels/
Extremely painful and destructive, gout is the most common form of inflammatory arthritis with elevated serum uric acid (sUA) a root cause of the disease. Even with the growing incidence of gout, recent research from the Gout & Uric Acid Education Society (GUAES) found that just 16 percent of Americans overall know the target sUA number for gout (6 mg/dL or below) – and just 38 percent of people with gout had their sUA levels checked within the past six months, the timeframe recommended by the American College of Rheumatology. Additionally, the majority of gout sufferers don’t understand the importance of taking daily uric acid-lowering medications, with four in 10 incorrectly believing that they can stop taking medications when they aren’t experiencing flares.
Seeking to increase recognition of the severity of gout and need for routine sUA testing and management, GUAES hosted a professional roundtable discussion on October 3, 2015. The roundtable brought together several experts – rheumatologists, a family care physician, and representatives from the American Association of Diabetes Educators, the National Kidney Foundation and CreakyJoints – to explore how to more effectively educate about gout and improve access to public education and treatment.
To view the multimedia release go to:
http://www.multivu.com/players/English/7715851-guaes-gout-roundtable-discussion/
AARP Travel’s (http://travel.aarp.org) newest research on Celebration Vacations is brought to life by AARP Travel Ambassador Samantha Brown in a new video available for download. Brown explains why Celebration Vacations are a popular way for America’s 76 million baby boomers to commemorate special milestones in life – such as anniversaries, birthdays, family reunions and weddings.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/66070-aarp-new-travel-website/
Virginia Bioinformatics Institute (VBI), a world-class research institute dedicated to the study of information biology, is using DataDirect Networks (DDN) SFA® high-performance storage engine-based GRIDScaler GPFS parallel file system to perform rapid, accurate Ebola outbreak modeling for the U.S. Department of Defense’s Defense Threat Reduction Agency (DTRA).
A team of 30 researchers and scientists on VBI’s Ebola rapid response team initially provided DTRA and West Africa’s Ministries of Health (MOH) with short-term forecasts on vaccine production and disease spread.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7429756-ddn-gridscaler-vbi-ebola/
High-powered research teams supported by the Crohn's & Colitis Foundation of America (CCFA) are gearing up for an ambitious new goal: developing individualized treatment approaches for patients with Crohn's disease and ulcerative colitis (UC), also known as inflammatory bowel diseases (IBD), through their Genetics and Microbiome Research Initiatives.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/65964-ccfa-genetic-microbiome-discoveries-ibd-crohn-s-disease-ulcerative-colitis
Tektronix, Inc., a leading worldwide provider of test, measurement and monitoring instrumentation, has introduced a new class of affordable spectrum analyzers based on a USB architecture with a list price of just $3,490. The new RSA306 sets a new price/performance threshold for spectrum analyzers and features a broad 9 kHz to 6.2 GHz frequency range, 40 MHz real time bandwidth and weighs in at just 1.2 pounds. When used with Tektronix SignalVu-PC software, it offers advanced analysis capabilities for such applications as budget-conscious research and development, mobile radio network installation, interference hunting and university level lab classes.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7074356-tektronix-announces-affordable-full-featured-portable-spectrum-analyzer/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Seeking to support men and their loved ones facing the challenges that come with a diagnosis of prostate cancer, USA Rugby, the Australian Rugby Union and Astellas Pharma have partnered to launch the #pass4prostate challenge, a social media campaign designed to generate awareness of prostate cancer and support a donation of up to $125,000 from Astellas to four research and advocacy organizations: Prostate Cancer Foundation, Australia Prostate Cancer Research, Prostate Cancer Foundation Australia and Prostate Cancer Canada.
From August 5 through the end of September – Prostate Cancer Awareness Month – social media users are encouraged to record a video of themselves catching an inanimate object, mentioning why prostate cancer awareness is important to them, and then passing that object, rugby-style, symbolically to a friend or family member. Astellas will donate $5 to prostate cancer advocacy organizations for every qualifying submission with the #pass4prostate hashtag posted to Facebook, Twitter or Instagram, up to a maximum contribution of $125,000.
To view the multimedia release visit:
http://www.multivu.com/players/English/7579051-pass4prostate-challenge-rugby-astellas/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
For Autumn-Winter 2014/15, Alberto Guardiani has created a futuristic collection where the trait d’union connecting tradition and the future is ongoing experimentation and design research; the lightness of innovative materials, the cuts of the leather, and the artisan craftsmanship are expertly combined with the functionality of the designs.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/72762526-alberto-guardiani-collection/
